STOCK TITAN

Heron Therapeutics Inc - HRTX STOCK NEWS

Welcome to our dedicated news page for Heron Therapeutics (Ticker: HRTX), a resource for investors and traders seeking the latest updates and insights on Heron Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Heron Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Heron Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.35%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.16%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.66%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.38%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.75%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.37%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.11%
Tags
fda approval
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.13%
Tags
none
Heron Therapeutics Inc

Nasdaq:HRTX

HRTX Rankings

HRTX Stock Data

411.90M
122.09M
0.89%
76.09%
16.35%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About HRTX

heron therapeutics, inc. (formerly a.p. pharma, inc.) is a specialty pharmaceutical company developing products using its proprietary biochronomer™ polymer-based drug delivery platform. this drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks.